Ramesh Swaminathan, Global CFO of Lupin discusses the impact of Trump's win on the Indian pharmaceutical sector. Growing ...

CEO Vinita Gupta stated that Lupin expects to maintain a quarterly range of $220-230 million for its US business, driven by ...

Lupin Q2 Results Live : Lupin declared their Q2 results on November 7, 2024, reporting a robust performance with a topline ...

Macquarie analysts described the results as an "all-round beat". Although revenue aligned closely with their forecast, Ebitda ...

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...

The company posted a net profit of Rs 852.6 crore in the quarter ended September in comparison to Rs 489.7 crore in the ...

Pharma major Lupin Ltd reported a robust 74.1% year-on-year rise in its consolidated net profit, reaching Rs 852.63 crore for ...

Lupin’s average revenue will potentially increase 9.2 per cent Y-o-Y to Rs 5,502 crore as against Rs 5,038 crore in Q2FY24.

Lupin Ltd (BOM:500257) reports robust financial performance with significant gains in India and US markets, while navigating competitive challenges and FDA compliance issues.

Lupin-the country's leading pharma major is slated to report its Q2 earnings later today. Zee Business research estimates the company to report decent performance with consolidated net profit seen to ...

Indian generic drugmaker Lupin reported a bigger-than-expected rise in second-quarter profit on Thursday, driven by strong demand for its respiratory and diabetes management drugs.

Lupin Limited delivered a strong financial performance for the second quarter, surpassing market expectations. Net profit for ...